Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases

References

• Marr KA. Fungal infections in oncology patients: update on epidemiology, prevention, and treatment. Curr Opin Oncol 2010;22(2):138-42
   PubMed Web of Science ®Google Scholar
• Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect 2014;20(Suppl 6):5-10
   Web of Science ®Google Scholar
• Petrikkos G, Skiada A, Drogari-Apiranthitou M. Epidemiology of mucormycosis in Europe. Clin Microbiol Infect 2014;20(Suppl 6):67-73
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006;91(8):1068-75
   PubMed Web of Science ®Google Scholar
• Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32(9):1319-24
   PubMed Web of Science ®Google Scholar
• Chandrasekar P. Diagnostic challenges and recent advances in the early management of invasive fungal infections. Eur J Haematol 2010;84(4):281-90
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Denning DW. New and emerging treatments for fungal infections. J Antimicrob Chemother 2008;61(Suppl 1):i19-30
   PubMed Web of Science ®Google Scholar
• Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011;86(8):805-17
   PubMed Web of Science ®Google Scholar
• Thompson GR3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010;170(5):291-313
   PubMed Web of Science ®Google Scholar
• Falci DR, Pasqualotto AC. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist 2013;6:163-74
   PubMedGoogle Scholar
• Livermore J, Hope W. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin Drug Metab Toxicol 2012;8(6):759-65
   PubMed Web of Science ®Google Scholar
• Martin de la Escalera C, Aller AI, Lopez-Oviedo E, et al. Activity of BAL 4815 against filamentous fungi. J Antimicrob Chemother 2008;61(5):1083-6
   PubMed Web of Science ®Google Scholar
• Rudramurthy SM, Chakrabarti A, Geertsen E, et al. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn Microbiol Infect Dis 2011;71(4):370-7
   PubMed Web of Science ®Google Scholar
• Shivaprakash MR, Geertsen E, Chakrabarti A, et al. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs. Mycoses 2011;54(5):e583-9
   Web of Science ®Google Scholar
• Perkhofer S, Lechner V, Lass-Florl C. In vitro activity of Isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2009;53(4):1645-7
   PubMed Web of Science ®Google Scholar
• Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008;52(4):1396-400
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Denning DW. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006;57(1):135-8
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for Aspergillus spp. for the CLSI M38-A2 broth microdilution method. Antimicrob Agents Chemother 2013;57(8):3823-8
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Rijs AJ, Melchers WJ, et al. In vitro activity of isavuconazole compared with itraconazole, voriconazole, and posaconazole in azole-resistant Aspergillus fumigatus [M-1377]. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Denver, Co 2013
   Google Scholar
• Gregson L, Goodwin J, Johnson A, et al. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole. Antimicrob Agents Chemother 2013;57(11):5778-80
   PubMed Web of Science ®Google Scholar
• Odds FC. Drug evaluation: BAL-8557–a novel broad-spectrum triazole antifungal. Curr Opin Investig Drugs 2006;7(8):766-72
   PubMedGoogle Scholar
• Available from: http://clinicaltrials.gov
   Google Scholar
• Astellas Pharma. Reports isavuconazole granted orphan drug designation by US FDA. Clin Infect Dis 2013;57: Ii-Ii
   Web of Science ®Google Scholar
• Basilea Pharmaceutica. Basilea reports that isavuconazole received QIDP designation from U.S. FDA for the treatment of invasive candidiasis. 16 edition. Basel, Switzerland: 2014. Available from: http://www.basilea.com/News-and-Media/
   Google Scholar
• Basilea Pharmaceutica. Basilea submits isavuconazole European Marketing Authorization Application for the treatment of invasive mold infections. 17 edition. Basilea Pharmaceutica; Basel, Switzerland: 2014. Available from: http://www.basilea.com/News-and-Media/
   Google Scholar
• European Medicines Agency (EMA). European public assessment report (EPAR) for Noxafil. 2012
   Google Scholar
• European Medicines Agency (EMA). European public assessment report (EPAR) for Vfend. 2012
   Google Scholar
• Warrilow AG, Martel CM, Parker JE, et al. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51). Antimicrob Agents Chemother 2010;54(10):4235-45
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). European public assessment report (EPAR) for Diflucan. 2012
   Google Scholar
• Sun HY, Singh N. Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis 2011;11(4):301-11
   PubMed Web of Science ®Google Scholar
• Lewis RE, Liao G, Wang W, et al. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence 2011;2(4):348-55
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46(3):327-60
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347(6):408-15
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356(4):348-59
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356(4):335-47
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Mouton JW, Verweij PE, Bruggemann RJ. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Rev Anti Infect Ther 2013;11(9):931-41
   PubMed Web of Science ®Google Scholar
• Vermeulen E, Lagrou K, Verweij PE. Azole resistance in Aspergillus fumigatus: a growing public health concern. Curr Opin Infect Dis 2013;26(6):493-500
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Perfect JR. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008;46(1):120-8
   PubMed Web of Science ®Google Scholar
• Girmenia C. New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 2009;18(9):1279-95
   PubMed Web of Science ®Google Scholar
• Turel O. Newer antifungal agents. Expert Rev Anti Infect Ther 2011;9(3):325-38
   PubMed Web of Science ®Google Scholar
• Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new oral triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother 1998;42(2):313-18
   PubMed Web of Science ®Google Scholar
• Yamazumi T, Pfaller MA, Messer SA, et al. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother 2000;44(10):2883-6
   PubMed Web of Science ®Google Scholar
• Moore CB, Walls CM, Denning DW. In vitro activity of the new triazole BMS-207147 against Aspergillus species in comparison with itraconazole and amphotericin B. Antimicrob Agents Chemother 2000;44(2):441-3
   PubMed Web of Science ®Google Scholar
• Guillon R, Pagniez F, Picot C, et al. Discovery of a novel broad-spectrum antifungal agent derived from albaconazole. ACS Med Chem Lett 2013;4(2):288-92
   PubMed Web of Science ®Google Scholar
• Bartroli J, Turmo E, Alguero M, et al. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. J Med Chem 1998;41(11):1869-82
   PubMed Web of Science ®Google Scholar
• Miller JL, Schell WA, Wills EA, et al. In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother 2004;48(2):384-7
   PubMed Web of Science ®Google Scholar
• Efficacy Vulvovaginitis Candida. Available from: http://clinicaltrials.gov/show/NCT00199264
   Google Scholar
• A study to evaluate efficacy and safety of three w0027 regimens in the treatment of moccasin type tinea pedis (MTTP). Available from: http://clinicaltrials.gov/show/NCT00509275
   Google Scholar
• Efficacy and safety study of 4 dose regimens of oral albaconazole in subjects with distal subungual onychomycosis. Available from: http://clinicaltrials.gov/show/NCT00730405
   Google Scholar
• Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clini Microbiol 2001;39(3):954-8
   PubMed Web of Science ®Google Scholar
• Ramos G, Cuenca-Estrella M, Monzon A, Rodriguez-Tudela JL. In-vitro comparative activity of UR-9825, itraconazole and fluconazole against clinical isolates of Candida spp. J Antimicrob Chemother 1999;44(2):283-6
   PubMed Web of Science ®Google Scholar
• Bartroli X, Uriach J. A clinical multicenter study comparing efficacy and tolerability between five single oral doses of albaconazole and fl uconazole 150 mg single dose in acute vulvovaginal candidiasis. In: 45th Interscience Conference on Antimicrobial Agents Chemotherapy (ICAAC). Washington, DC; 2005
   Google Scholar
• Ohwada J, Tsukazaki M, Hayase T, et al. Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. Bioorg Med Chem Lett 2003;13(2):191-6
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50(1):286-93
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 2006;50(1):279-85
   PubMed Web of Science ®Google Scholar
• Mohr J, Johnson M, Cooper T, et al. Current options in antifungal pharmacotherapy. Pharmacotherapy 2008;28(5):614-45
   PubMed Web of Science ®Google Scholar
• Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003;17(1):159-91; ix
   PubMed Web of Science ®Google Scholar
• Fromtling RA. Overview of medically important antifungal azole derivatives. Clin Microbiol Rev 1988;1(2):187-217
   PubMedGoogle Scholar
• Denning DW, Hope WW. Therapy for fungal diseases: opportunities and priorities. Trends Microbiol 2010;18(5):195-204
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bohme A, Reichert D, et al. Pharmacokinetics, safety and tolerability results from a dose escalation study of isavuconazole in neutropenic patients [M-2137]. In: 48th annual international interscience conference on antimicrobial agents and chemotherapy (ICAAC). American Society for Microbiology; Washington; 2008
   Google Scholar
• Schmitt-Hoffmann A, Roos B, Heep M. Steady-state bioavailability of oral isavuconazole in healthy volunteers. Int J Antimicrob Agents 2007;29:S262-2
   Web of Science ®Google Scholar
• Schmitt-Hoffman A, Roos B, Roehrle M, et al. No relevant food effect in man on isavuconazole oral pharmacokinetics preliminary data. In: 48th international interscience conference on antimicrobial agents and chemotherapy (ICAAC). American Society for Microbiology; Washington; 2008
   Google Scholar
• Schmitt-Hoffmann A, Roos B, Spickermann J, et al. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557. Antimicrob Agents Chemother 2009;53(11):4885-90
   PubMed Web of Science ®Google Scholar
• Heep M, Roos B, Sochor M, et al. QTc measurements during a placebo- and actively controlled multiple dose study of two different dosing regimen of isavuconazole [P-1675]. In: 17th annual European congress of clinical microbiology and infectious diseases (ECCMID). Munich; 2007
   Google Scholar
• Schmitt-Hoffman A, Roos B, Sauer J. Effect of rifampicin on the pharmacokinetics of BAL4815 at steady state after multiple oral doses of BAL8557 (WSA) and rifampicin [P-0319]. In: 16th congress of the international society for human and animal mycology (ISHAM). Paris, France; 2006
   Google Scholar
• Schmitt-Hoffman A, Roos B, Sauer J. Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of S- and R-warfarin [P-0321]. In: 16th congress of the international society for human and animal mycology (ISHAM). Paris, France; 2006
   Google Scholar
• Schmitt-Hoffman A, Roos B, Sauer J. Effect of BAL8557, a water-soluble azole pro-drug (WSA), on the pharmacokinetics of ciclosporin [P-0136]. In: 16th congress of the international society for human and animal mycology (ISHAM). Paris, France; 2006
   Google Scholar
• Schmitt-Hoffman A, Roos B, Sauer J, et al. Effect of BAL8557, a Water-soluble Azole Pro-Drug (WSA) on the pharmacokinetics of Tacrolimus [P-0320]. In: 16th international society of human and animal mycoses (ISHAM). Paris, France; 2006
   Google Scholar
• Arendrup MC, Howard S, Lass-Florl C, et al. EUCAST testing of isavuconazole susceptibility in aspergillus: comparison of results for inoculum standardization using conidium counting versus optical density. Antimicrob Agents Chemother 2014;58(11):6432-6
   PubMed Web of Science ®Google Scholar
• Meis JF, Mouton JW, Bouchara JP, et al. In vitro activity of isavuconazole against a worldwide collection of 237 Aspergillus section Terrei isolates and compared with 7 other Aspergillus active antifungal drugs tested with EUCAST and CLSI methodology [M-332]. In: 52rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA; 2012
   Google Scholar
• Datta K, Rhee P, Byrnes E3rd, et al. Isavuconazole activity against Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J Clin Microbiol 2013;51(9):3090-3
   PubMed Web of Science ®Google Scholar
• Castanheira M, Messer SA, Rhomberg PR, et al. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values. Mycopathologia 2014;178(1-2):1-9
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 2013;51(8):2608-16
   PubMed Web of Science ®Google Scholar
• Yamazaki T, Inagaki Y, Fujii T, et al. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. Int J Antimicrob Agents 2010;36(4):324-31
   PubMed Web of Science ®Google Scholar
• Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007;51(5):1818-21
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Messer SA, et al. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. Diagn Microbiol Infect Dis 2014;79(2):198-204
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, et al. Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. J Clin Microbiol 2010;48(12):4580-5
   PubMed Web of Science ®Google Scholar
• Gonzalez G. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 2009;47(1):71-6
   PubMed Web of Science ®Google Scholar
• Guinea J, Pelaez T, Recio S, et al. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species (vol 52, pg 1396, 2008). Antimicrob Agents Chemother 2008;52(11):4211-11
   Web of Science ®Google Scholar
• Verweij PE, Gonzalez GM, Wiedrhold NP, et al. In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries. J Chemother 2009;21(3):272-81
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Kathuria S, Singh PK, et al. Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India. Mycoses 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• . Espinel-Ingroff A, Chowdhary A, Gonzalez GM, et al.Isavuconazole MIC. Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex by the CLSI Broth Microdilution Method (M27-A3 document): a Multicenter Study. Antimicrob Agents Chemother 2014; Epub ahead of print
   Web of Science ®Google Scholar
• Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, et al. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 2008;52(4):1580-2
   PubMed Web of Science ®Google Scholar
• Thompson GR3rd, Wiederhold NP, Fothergill AW, et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2009;53(1):309-11
   PubMed Web of Science ®Google Scholar
• Thompson GR3rd, Fothergill AW, Wiederhold NP, et al. Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 2008;52(8):2959-61
   PubMed Web of Science ®Google Scholar
• Hagen F, Illnait-Zaragozi MT, Bartlett KH, et al. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 2010;54(12):5139-45
   PubMed Web of Science ®Google Scholar
• Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011;11(2):142-51
   PubMed Web of Science ®Google Scholar
• Hofmeyr A, Slavin MA. Emerging opportunistic yeast infections in haematology patients. Leuk Lymphoma 2006;47(9):1736-7
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004;42(10):4419-31
   PubMed Web of Science ®Google Scholar
• Guinea J, Recio S, Escribano P, et al. In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. Antimicrob Agents Chemother 2010;54(9):4012-15
   PubMed Web of Science ®Google Scholar
• Thompson GR3rd, Wiederhold NP, Sutton DA, et al. In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother 2009;64(1):79-83
   PubMed Web of Science ®Google Scholar
• Hazirolan G, Canton E, Sahin S, Arikan-Akdagli S. Head-to-head comparison of inhibitory and fungicidal activities of fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole against clinical isolates of Trichosporon asahii. Antimicrob Agents Chemother 2013;57(10):4841-7
   PubMed Web of Science ®Google Scholar
• Bell WR, Dalton JB, McCall CM, et al. Iatrogenic Exserohilum infection of the central nervous system: mycological identification and histopathological findings. Mod Pathol 2013;26(2):166-70
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Pham CD, Gade L, et al. Preliminary laboratory report of fungal infections associated with contaminated methylprednisolone injections. J Clin Microbiol 2013;51(8):2654-61
   PubMed Web of Science ®Google Scholar
• Moradi PW, Petraitis V, Petraitiene R, et al. Activity of isavuconazole, amphotericin B, and micafungin alone and in combination against exserohilum rostratum [M-1372]. In: 53rd interscience conference on antimicrobial agents and chemotherapy (ICAAC). Denver, Co 2013
   Google Scholar
• Seyedmousavi S, Guillot J, de Hoog GS. Phaeohyphomycoses, emerging opportunistic diseases in animals. Clin Microbiol Rev 2013;26(1):19-35
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Ajello L, Matsuda T, et al. Developments in hyalohyphomycosis and phaeohyphomycosis. J Med Vet Mycol 1994;32(Suppl 1):329-49
   PubMedGoogle Scholar
• Revankar SG, Sutton DA. Melanized fungi in human disease. Clin Microbiol Rev 2010;23(4):884-928
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Padhye AA, Ajello L. Medical significance of the so-called black yeasts. Eur J Epidemiol 1987;3(2):87-95
   PubMed Web of Science ®Google Scholar
• Najafzadeh MJ, Sutton DA, Keisari MS, et al. In vitro activities of eight antifungal drugs against 104 environmental and clinical isolates of Aureobasidium pullulans. Antimicrob Agents Chemother 2014;58(9):5629-31
   PubMed Web of Science ®Google Scholar
• Najafzadeh MJ, Saradeghi Keisari M, Vicente VA, et al. In vitro activities of eight antifungal drugs against 106 waterborne and cutaneous Exophiala species. Antimicrob Agents Chemother 2013;57(12):6395-8
   PubMed Web of Science ®Google Scholar
• Badali H, De Hoog GS, Curfs-Breuker I, Meis JF. Antifungal activity of isavuconazole and 7 other drugs against Cladophialophora spp., related to chromoblastomycosis. Mycoses 2009;52:102-3
   Web of Science ®Google Scholar
• Deng S, de Hoog GS, Badali H, et al. In vitro antifungal susceptibility of Cladophialophora carrionii, an agent of human chromoblastomycosis. Antimicrob Agents Chemother 2013;57(4):1974-7
   PubMed Web of Science ®Google Scholar
• Feng P, Najafzadeh MJ, Sun J, et al. In vitro activities of nine antifungal drugs against 81 Phialophora and Cyphellophora isolates. Antimicrob Agents Chemother 2012;56(11):6044-7
   PubMed Web of Science ®Google Scholar
• Kloezen W, Meis JF, Curfs-Breuker I, et al. In vitro antifungal activity of isavuconazole against Madurella mycetomatis. Antimicrob Agents Chemother 2012;56(11):6054-6
   PubMed Web of Science ®Google Scholar
• Lackner M, de Hoog GS, Verweij PE, et al. Species-specific antifungal susceptibility patterns of Scedosporium and Pseudallescheria species. Antimicrob Agents Chemother 2012;56(5):2635-42
   PubMed Web of Science ®Google Scholar
• Verweij PE, Mellado E, Melchers WJ. Multiple-triazole-resistant aspergillosis. N Engl J Med 2007;356(14):1481-3
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J Clin Microbiol 2007;45(1):70-5
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L, et al. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J Clin Microbiol 2008;46(2):551-9
   PubMed Web of Science ®Google Scholar
• Auberger J, Lass-Florl C, Aigner M, et al. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother 2012;67(9):2268-73
   PubMed Web of Science ®Google Scholar
• Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004;39(5):743-6
   PubMed Web of Science ®Google Scholar
• Magill SS, Shields C, Sears CL, et al. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006;44(2):529-35
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Calabrese D, et al. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob Agents Chemother 1999;43(11):2753-65
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, Fiori B, et al. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother 2005;49(2):668-79
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Coste A, Rerrari S. Comparison between isavuconazole (ISA) and other azoles against characterized clinical isolates and yeast model systems [P-2176]. In: 18th European congress of clinical microbiology and infectious diseases (ECCMID). Barcelona; 2008
   Google Scholar
• Lepak AJ, Marchillo K, Vanhecker J, Andes DR. Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus. Antimicrob Agents Chemother 2013;57(12):6284-9
   PubMed Web of Science ®Google Scholar
• Seyedmousavi S, Meis JF, Bruggemann RJ, et al. Pharmacodynamics of the new azole isavuconazole in an Aspergillus fumigatus mouse infection model [P1698]. In: 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Baecelona; 2014
   Google Scholar
• Warn PA, Sharp A, Mosquera J, et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 2006;58(6):1198-207
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Marchillo K, VanHecker J, et al. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob Agents Chemother 2013;57(11):5642-8
   PubMed Web of Science ®Google Scholar
• Warn PA, Sharp A, Parmar A, et al. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob Agents Chemother 2009;53(8):3453-61
   PubMed Web of Science ®Google Scholar
• Majithiya J, Sharp A, Parmar A, et al. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 2009;63(1):161-6
   PubMed Web of Science ®Google Scholar
• Te Dorsthorst DT, Verweij PE, Meis JF, Mouton JW. Pharmacodynamics of BAL4815 a new azole antifungal in a mouse model of systemic infection [A–1874]. In: 14th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID). Prague, Czech Republic; 2004
   Google Scholar
• Ervens J, Ghannoum M, Graf B, Schwartz S. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection 2014;42(2):429-32
   PubMed Web of Science ®Google Scholar
• Luo G, Gebremariam T, Lee H, et al. Isavuconazole therapy protects immunosuppressed mice from mucormycosis. Antimicrob Agents Chemother 2014;58(4):2450-3
   PubMed Web of Science ®Google Scholar
• Peixoto D, Gagne LS, Hammond SP, et al. Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol 2014;52(3):1016-19
   PubMed Web of Science ®Google Scholar
• Isavuconazole (BAL8557) for primary treatment of invasive aspergillosis. Available from: http://clinicaltrials.gov/show/NCT00412893
   Google Scholar
• Maertens J, Patterson T, Rahav G, et al. A phase 3 randomised, double –binded trial evaluating isavuconazole vs. voriconazole for the primary treatment of invasive fungal disease caused by Aspergillus spp. or other filamentous fungi (SECURE) [O230a]. In: 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Barcelona; 2013
   Google Scholar
• Isavuconazole in the treatment of renally impaired aspergillosis and rare fungi (VICAL). Available from: http://clinicaltrials.gov/show/NCT00634049
   Google Scholar
• Isavuconazole (BAL8557) in the treatment of candidemia and other invasive candida infections. Available from: http://clinicaltrials.gov/show/NCT00413218
   Google Scholar